Rare Tumors, published by SAGE Publications Ltd, is a premier open-access journal dedicated to advancing the understanding and research of rare neoplasms. With the ISSN 2036-3605 and E-ISSN 2036-3613, this journal provides a vital platform for sharing innovative research findings and clinical insights since its inception in 2009. Situated in Italy, Rare Tumors has a converged publication timeline from 2010 to 2024 and aims to foster a supportive community for researchers and professionals in the oncology and histology fields. It has achieved a notable Q3 ranking in Oncology and Q4 in Histology as of 2023, reflecting its crucial role in bridging the knowledge gap in these specialized areas. Despite its relatively humble Scopus ranks, the journal's open-access model ensures that vital information reaches a broad audience, including those in academia, clinical practice, and beyond. It aspires to not only document rare tumor cases but also stimulate dialogue on their diagnosis, treatment, and management strategies, making it an indispensable resource for anyone dedicated to tackling the challenges posed by rare tumors.

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.

Case Reports in Immunology, published by HINDAWI LTD, is an esteemed open-access journal that has been contributing to the field of immunology since its launch in 2011. With both ISSN 2090-6609 and E-ISSN 2090-6617, the journal provides a platform for researchers to publish detailed case reports that explore diverse immunological conditions and novel treatment approaches. This journal is crucial for clinicians, researchers, and students alike, seeking to broaden their understanding of immunology's practical applications and advances. As of 2023, it holds a Q3 ranking in Immunology and Q2 in Immunology and Allergy, reflecting its growing relevance and contribution to the field. Additionally, it is indexed in Scopus, where it ranks #178 in Immunology and Allergy and #192 in Immunology and Microbiology, enhancing its visibility and impact. With a comprehensive accessibility model, the journal is dedicated to disseminating knowledge widely and enriching discussions in immunological research.

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, published by Lippincott Williams & Wilkins, serves as a vital platform for the dissemination of cutting-edge research and insights in the fields of pediatric hematology and oncology. Since its inception in 1979, the journal has maintained a commitment to advancing knowledge through peer-reviewed articles that contribute to the understanding and treatment of blood disorders and cancers in children. With an impact factor reflective of its academic contributions, the journal is positioned in the Q3 quartile across key medical categories — Hematology, Oncology, and Pediatrics, Perinatology and Child Health — indicating its relevance and influence in the field. While it does not currently offer open access options, the journal remains a crucial resource for researchers, clinicians, and students dedicated to improving pediatric care and outcomes. Researchers are encouraged to contribute to this esteemed journal as it seeks to bridge the gap between clinical practice and research, fostering innovation and improved quality of life for young patients affected by hematologic and oncologic conditions.

Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.